A clinical trial published last week in the medical journalNeurology has shown that a reduced time period between treatments when switching from natalizumab (Tysabri) to fingolimod (Gilenya) is beneficial. To read the full article click on the following link
Article courtesy of MS Research Australia www.msra.org.au